

GOLD FIELDS LTD

Form 6-K

May 05, 2008

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16**

**of the Securities Exchange Act of 1934**

For the month of May 2008

Commission File Number 1-31318

**Gold Fields Limited**

(Translation of registrant's name into English)

24 St. Andrews Rd.

Parktown, 2193

South Africa

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F..x... Form 40-F.....

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ..... No ..x...

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- \_\_\_\_\_

Directors: A J Wright (Chairman), I D Cockerill

†  
(Chief Executive Officer), K Ansah

#  
, N J Holland

†  
(Chief Financial Officer), J G Hopwood, G Marcus, J  
M McMahon

†  
, D N Murray,  
D M J Ncube, R L Pennant-Rea

†  
, P J Ryan, C I von Christierson

†  
British,

#  
Ghanaian  
Corporate Secretary: C Farrel  
Gold Fields Limited  
Reg. 1968/004880/06  
24 St Andrews Road  
Parktown, 2193

Postnet Suite 252  
Private Bag X30500  
Houghton, 2041  
South Africa

Tel +27 11 644-2400  
Fax +27 11 484-0639  
[www.goldfields.co.za](http://www.goldfields.co.za)

**Enquires**

Reidwaan Wookay  
Tel  
+27 11 644-2665  
Fax  
+27 11 484-0639  
Mobile 084 878 4566

Andrew Davidson  
Tel  
+27 11 644-2638  
Fax  
+27 11 484-0639  
Mobile 082 667 7203

MEDIA RELEASE

**Memorial Service and Day of Mourning  
to be held at South Deep**

**Johannesburg May 4, 2008:** Gold Fields Limited (“Gold Fields”) (NYSE, JSE, DIFX: GFI) said today that a Memorial Service would be held at the Twin Shafts complex of South Deep gold mine, near Westonaria, on Wednesday, May 7, 2008 following the tragic shaft accident on Thursday, May 1, 2008 in which nine colleagues lost their lives and the fall of ground accident that occurred on April 29 in which one colleague lost his life.

A letter, signed jointly by the South Deep management and the trade unions, has been sent to employees on the mine informing them of the Memorial Service and pointing out that Wednesday May 7, 2008 has been set aside as a Day of Mourning. The Day of Mourning will commence at the beginning of the night shift on Tuesday May 6, 2008.

In the letter, the Head of the Operations, South Deep, Stuart Allan, the Branch Chairperson of the National Union of Mineworkers (NUM), Kanetso Matabane and the full-time representative of the United Associations of South Africa, (UASA) Pieter Nel, inform employees of their commitment to co-operate with the Department of Minerals and Energy (DME) in its investigation into the shaft accident.

The DME issued a Section 54 order at 17h40 on May 1, 2008 - the day of the shaft accident – instructing that all winding operations at South Deep, Kloof and Driefontein Gold Mines be suspended pending the assessment of the integrity of the winding ropes. The suspension order was lifted on May 2, 2008 in respect of all main winders transporting men, material and rocks.

In respect of service winders and elevators, testing is continuing and is expected to be completed in the week commencing May 5, 2008, upon which the order, in respect of the service winders and elevators, is expected to be lifted. These service winders and elevators remain inoperative pending the lifting of the order.

Mining operations at Kloof and Driefontein have resumed. No mining operations will take place at South Deep until the Principal Inspector of Mines (Gauteng Region) has met with management and unions on Monday May 5, 2008 at 10h30.

-2-

Contrary to certain media reports, the Section 54 issued by the DME in respect of South Deep was fully complied with and, subsequent to the issue thereof, only essential services for emergency purposes were conducted underground at South Deep.

All underground employees at South Deep have been advised not to report for duty until the night shift of Monday, May 5, 2008.

Mine management will continue to assist the bereaved relatives.

Gold Fields Limited reiterates its commitment to assist the DME in its investigation into the tragic accident at South Deep on May 1, 2008 and to take measures to try and ensure that no harm comes to any of its employees while at work.

The names of the deceased from the South Deep shaft accident are being withheld until the bereaved families give permission for the names to be released.

#### **Enquiries**

Andrew Davidson  
Office 011-644-2368  
Mobile 0826677203  
ends

#### **About Gold Fields**

*Gold Fields Limited is one of the world's largest unhedged producers of gold with attributable production of more than four million ounces per annum from eight operating mines in South Africa, Ghana and Australia.*

*A ninth mine, the Cerro Corona Gold/Copper mine in Peru, is expected to commence production by mid 2008 at an initial rate of approximately 400,000 gold equivalent ounces per annum.*

*The company has total attributable ore reserves of 92 million ounces and mineral resources of 252 million ounces. Gold Fields employs some 53,000 permanent employees across its operations and is listed on the JSE Limited South Africa (primary listing), the New York Stock Exchange (NYSE) and the Dubai International Financial Exchange (DIFX). All of Gold Fields' operations are ISO14001 certified. For more information please visit the Gold Fields website at [www.goldfields.co.za](http://www.goldfields.co.za)*

## Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: 4 May 2008

## GOLD FIELDS LIMITED

By:

Name: Mr W J Jacobsz

Title: Senior Vice President: Investor  
Relations and Corporate Affairs

I statements and other related disclosures required to be included in our Form 10-K.

The reasons discussed above causing our inability to timely file our Annual Report on Form 10-K for the year ended December 31, 2007 cannot be eliminated without unreasonable effort or expense. Our Form 10-K will be filed no later than the fifteenth calendar day following the prescribed due date.

This Notification of Late Filing on Form 12b-25 includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. For this purpose, any statements about our future expectations, plans and prospects, including, without limitation, statements regarding our strategy, future operations, financial position, future revenues, and projected costs, prospects, plans and objectives of management, and all other statements that are not purely historical in nature, constitute forward-looking statements. Without limiting the foregoing, the words anticipate, believe, could, estimate, expect, intend, may, plan, project, should, will, wo expressions are intended to identify forward-looking statements. In particular, any statements regarding our ongoing review of strategic alternatives are forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties relating to: our ability to successfully market and sell ZYFLO CR (zileuton) extended-release tablets, including the success of our co-promotion arrangement with Dey, L.P., or DEY; our ability to transition our management team effectively; our current review of our business strategy and future operations, and the implementation of changes in our strategy and future operations, if any, approved by our board of directors; our ability to develop and maintain the necessary sales, marketing, distribution and manufacturing capabilities to commercialize ZYFLO CR; patient, physician and third-party payor acceptance of ZYFLO CR as a safe and effective therapeutic product; adverse side effects experienced by patients taking ZYFLO CR or ZYFLO® (zileuton tablets), the immediate-release formulation of zileuton; our heavy dependence on the commercial success of ZYFLO CR; our ability to maintain regulatory approvals to market and sell ZYFLO CR; the success of our co-promotion arrangement with DEY for PERFOROMIST (formoterol fumarate) Inhalation Solution; our ability to successfully enter into additional strategic co-promotion, collaboration or licensing transactions on favorable terms, if at all; conducting clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to obtain the substantial additional funding required to conduct our development and commercialization activities; our dependence on our strategic collaboration with MedImmune, Inc.; and our ability to obtain, maintain and enforce patent and other intellectual property protection for ZYFLO CR, our discoveries and our drug candidates. These and other risks are described in greater detail in the Risk Factors section of our most recent Quarterly Report on Form 10-Q and other filings that we make with the Securities and Exchange Commission. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by our forward-looking statements.

In addition, the statements in this Form 12b-25 reflect our expectations and beliefs as of the date hereof. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any

obligation to do so, whether as a result of new information, future events or otherwise. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, business development transactions, joint ventures or investments we may make. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Form 12b-25.

(Attach extra Sheets if Needed)

**PART IV OTHER INFORMATION**

- (1) Name and telephone number of person to contact in regard to this notification

**Scott B. Townsend, Esq.**

**(781)**

**402-5700**

(Name)

(Area Code)

(Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes  No

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes  No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Not applicable.

**Critical Therapeutics, Inc.**

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date March 12, 2008

By /s/ Thomas P. Kelly

Thomas P. Kelly  
Chief Financial Officer and Senior  
Vice President of Finance and  
Corporate Development

4